Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Signi®cance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60 ± 65% in intramedullarly MM, 70 ± 80% in extramedullary MM, and 490% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (cmaf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3' enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell speci®c DNA modi®cation mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic eect, but instead increase proliferation and/or inhibit dierentiation. The fact that so many dierent primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell. Oncogene (2001) 20, 5611 ± 5622.
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Productive stimulation with antigen causes proliferation and dierentiation of B lymphocytes into two kinds of terminally dierentiated plasma cells (PC). Pre-germinal center (GC) PC, which can secrete IgM or undergo IgH switch recombination to secrete another isotype of immunoglobulin, do not have somatically hypermutated Ig genes. These PC usually are short-lived, surviving for about 3 days at their site of origin. In contrast, post-GC PC have undergone repeated rounds of somatic hypermutation and antigen selection before dierentiation to PC. Post-GC PC that have undergone IgH switch recombination to a nonIgM isotype typically migrate to the bone marrow where they interact with stromal cells as non-proliferative, long-lived PC that survive about 30 days but sometimes many years (MacLennan, 1998) .
Multiple myeloma (MM) is a malignant, progressive tumor of post-GC, long-lived PC that is closely associated with stromal cells, and is located at multiple sites in the bone marrow (Figure 1 ) (Kyle and Rajkumar, 1999; Malpas et al., 1998) . MM is often preceded by a premalignant tumor called Monoclonal Gammopathy of Uncertain Signi®cance (MGUS). In contrast to MM, MGUS constitutes less than 10% of mononuclear cells in the bone marrow, with the number of tumor cells remaining stable unless there is progression to malignant MM. MGUS converts at a rate of about 1% per year to frankly malignant MM that expresses the same Ig clonotype and isotype, with at least 30 ± 50% of MM preceded by MGUS. Intramedullary MM progresses within the bone marrow as manifested by an increasing fraction of mononuclear cells in the bone marrow being replaced by tumor cells. Terminally, MM can progress to an extramedullary form that is called secondary PC leukemia (PCL), but sometimes primary PCL occurs without prior recognition of intramedullary MM. MM cell lines are derived from primary or secondary PCL. All stages of the tumor have a very low capacity for proliferation, with the DNA labeling index typically progressing from 50.5% in MGUS to 51% in early MM and rarely up to 5 ± 10% of tumor cells in the most advanced stages of disease.
tumors, with about 80% of these derived from GC or post-GC B cells (Ries et al., 2000) . A possible explanation for the predominance of GC and post-GC tumors is that GC B cells can be subjected to three speci®c DNA modi®cations that generate double-stranded breaks in DNA, whereas T cells and pre-germinal center B cells are subjected only to VDJ recombination (and a limited amount of IgH switch recombination in antigen stimulated pre-GC B cells) (Max, 1999; Papavasiliou and Schatz, 2000) . Early in lymphopoiesis, B cells activate the lymphoid speci®c VDJ recombination mechanism to form and edit antigen receptors by sequential, regulated DNA rearrangements of the IgH and IgL loci. Late in the immune response, antigen stimulates B cell to undergo IgH switch recombination, which occurs primarily in GC B cells, and somatic hypermutation, which appears to occur exclusively in GC B cells. Errors in any of these three B cell speci®c DNA modi®cations, each of which can`spill over' to aect non-Ig genes, can result in chromosomal translocations, deletions, insertions, and even point mutations (Kuppers et al., 1999) .
In fact, a primary event in many kinds of B cell tumors is dysregulation of an oncogene that is juxtaposed near one of the potent Ig enhancers as a result of translocation to an IgH (14q32) locus or somewhat less often to an IgL (k, 2p11 or l, 22q11) locus (Dalla-Favera and Gaidano, 2001) . It is thought that most of these translocations are mediated by aberrant resolution of double-stranded DNA breaks, which occur at sites in the Ig locus that speci®cally are targeted by one of the three B cell speci®c DNA modi®cation mechanisms. The mechanism(s) by which double-stranded DNA breaks are generated in the partner chromosomes involved in translocations with an Ig locus are poorly understood. However, with rare exceptions, the partner breakpoint regions lack speci®c structural features that are thought to be targeted by the B cell speci®c mechanisms, but may be related to a variety of aberrations (e.g., ATM mutations) that in¯uence genetic stability (Vanasse et al., 1999; Welzel et al., 2001) . In any case, it is hypothesized that double-stranded DNA breaks on both chromosomes must occur at a stage in normal B cell development when these mechanisms are active. For example, most pre-germinal center mantle cell lymphoma (MCL) tumors have a t(11;14) translocation with the IgH breakpoints occurring at or very near the sites targeted by VDJ recombinase. In most cases, the der(14) breakpoint occurs immediately 5' to a JH segment and the der(11) breakpoint occurs immediately 3' to a D segment, consistent with the paired cleavage that occurs at these sites during normal DJ recombination (Welzel et al., 2001) . Despite ongoing somatic hypermutation in many germinal center follicular cell lymphoma (FCL) tumors, most tumors have a t(14;18) translocation with the location of the IgH breakpoints similar to those seen in MCL (Jager et al., 2000) . It is hypothesized that these transloca- Figure 1 Timing of primary and secondary translocations in the multi-step pathogenesis of MM. The top line is a diagram of the linear progression of plasma cell neoplasia, starting from a normal plasmablast. The benign plasma cell neoplasm MGUS progresses to malignant MM with a rate of about 1% per year. Initially this tumor is con®ned to the bone marrow (intra-medullary), but with time acquires the ability to grow in extra-medullary locations (blood, pleural¯uid, skin, etc.) . Some of these extra-medullary MM can establish immortalized cell lines in vitro. Ig translocations mediated by B cell speci®c mechanisms (somatic mutation and switch recombination) represent primary events in the transformation of the plasmablast. In MGUS it is evident that the cell has passed through a period of marked chromosomal instability, with gains and losses of whole chromosomes. It is possible that an underlying genetic instability may have contributed to the primary Ig translocation. With disease progression this chromosomal instability contributes to secondary translocations that do not appear to be mediated by B cell speci®c mechanisms. These translocations are associated with more aggressive growth of the tumor, including extra-medullary spread of the tumor tions must have occurred during Ig receptor formation in pre-B cells or receptor editing in immature B cells, although we cannot discount the possibility that VDJ recombinase can become active in some germinal center B cells.
Germinal center Burkitt's lymphoma (BL) tumors have t(8;14) translocations that do not appear to be mediated by the VDJ recombinase mechanisms (Goossens et al., 1998; Neri et al., 1988) . For most endemic BL tumors, the IgH breakpoints occur within VDJ regions or near downstream JH regions but not at or very near the sites targeted by VDJ recombinase, consistent with the hypothesis that the IgH breakpoints are mediated by the somatic hypermutation mechanism. In contrast, for most sporadic BL tumors, the IgH breakpoints occur within or immediately adjacent to IgH switch regions, suggesting that the IgH breakpoints are mediated by the IgH switch recombination mechanism. In some diuse large cell lymphoma (DLCL), the t(3;14) translocation appears to involve simultaneously two B cell speci®c mechanisms, an IgH switch recombinase mediated breakpoint in the IgH locus and a somatic hypermutation mediated breakpoint downstream of the promoter of the bcl-6 gene (Pasqualucci et al., 1998; Ye et al., 1995) .
Primary vs secondary translocations in MM
Primary translocations occur as early and perhaps initiating events during the pathogenesis of MM, whereas secondary translocations occur as progression events (Figure 1 ). For B cell tumors, most primary translocations are simple reciprocal translocations that juxtapose a partner chromosome (and oncogene) and one of the Ig enhancers, and are mediated by one of the three B cell speci®c DNA modi®cation mechanisms described above. For B cell tumors in which one or more of the three B cell DNA modi®cation mechanisms remain active, secondary translocations could be mediated by one of these mechanisms. However, for normal PC and PC tumors, it is thought that all three of the B cell DNA modi®cation mechanisms are inactive (with the possible exception of ongoing somatic hypermutation in some MGUS tumors) (Bakkus et al., 1992; Bergsagel et al., 1996; Sahota et al., 1996) . Therefore, unless one of these mechanisms could be re-activated, secondary translocations would be mediated by other kinds of recombination mechanisms that do not speci®cally target the Ig loci but could involve an Ig locus. Primary translocations would be present in premalignant MGUS, whereas secondary translocation are expected to be rare or absent in MGUS. Obviously, however, the only de®nitive way to distinguish primary from secondary translocations would be to document the time(s) at which translocations occur during the linear pathogenesis of individual tumors. In the absence of this de®nitive test, we propose other criteria that might distinguish primary from secondary translocations in MM (Table 1) .
Dysregulation of c-myc as a paradigm for secondary translocations in MM
Chromosomal translocations that dysregulate c-myc by juxtaposing it with one of the three Ig loci represent an essentially invariant and apparently primary event in human Burkitt's lymphoma and murine plasmacytoma tumors (Dalla-Favera et al., 1982; Shen-Ong et al., 1982) . The non-translocated c-myc allele is not expressed, corresponding to the absence of c-myc expression in resting germinal center B cells and terminally dierentiated plasma cells (Kakkis et al., 1989) . Despite the similarity in phenotype of human MM and murine plasmacytoma tumors, earlier studies identi®ed t(8;14) translocations, c-myc DNA rearrangements, or c-myc ampli®cation in less than 10% of MM tumors and cell lines (Calasanz et al., 1997; Dewald et al., 1985; Lai et al., 1995; Nishida et al., 1997; Sawyer et al., 1995) . Recently, however, it was determined that one c-myc allele is expressed selectively in all twelve informative MM cell lines that have polymorphic mutations that distinguish mRNA expressed from the maternal and paternal c-myc alleles (Shou et al., 2000; Kuehl, 2001, unpublished) . This result suggested cis-dysregulation of c-myc in all MM cell lines, and prompted a more sensitive molecular cytogenetic analysis of MM cell lines and tumors. Three color FISH analyses of metaphase chromosomes show that 25 of 29 (86%) MM cell lines and 17/38 (45%) advanced primary MM tumors have similar, complex karyotypic abnormalities involving the c-myc locus at 8q24.1. Strikingly, classical t(8;14) and t(8;22) reciprocal translocations comprise only 10 and 5%, respectively, of the c-myc karyotypic abnormalities that were detected. Most karyotypic abnormalities are complex translocations and insertions that often are non-reciprocal, and frequently involve three dierent chromosomes. In addition, associated deletions, inversions, duplications, and ampli®cation are sometimes seen. Most of these c-myc karyotypic abnormalities would not be detected by conventional cytogenetics, but some would be detected by SKY analyses. The karyotypic abnormalities often, but not always, juxtapose c-myc and an Ig enhancer, with 9/25 (36%) of MM cell lines and 8/17 (47%) of primary tumors having a karyotypic abnormality of c-myc that does not involve an apparent association with an Ig enhancer. By interphase FISH analyses, it is reported that c-myc is associated with the IgH locus in 3/140 MM tumors representing all stages, and in none of 79 MGUS tumors (Avet-Loiseau et al., 1999b) . Cloned t(8;14) translocation/insertion breakpoints often do not occur at the IgH sites targeted by the three B cell speci®c DNA modi®cations. In addition, there are at least two tumors in which karyotypic abnormalities of the c-myc locus are heterogeneous. All of these results support a model for MM in which dysregulation of cmyc occurs as a late, progression event that is mediated by secondary translocations that do not involve the three B cell speci®c DNA modi®cation mechanisms.
Identi®cation of Ig translocations in MM
Karyotypic analyses of MM tumors using conventional cytogenetic methods greatly underestimated the incidence of IgH translocations, and rarely identi®ed the partner chromosome except for t(11;14) (Calasanz et al., 1997; Dewald et al., 1985; Lai et al., 1995; Sawyer et al., 1995) . At least three problems are responsible for the inability of conventional cytogenetic analyses of metaphase chromosomes to detect IgH translocations in MM. First, MM tumors have a very low mitotic index even when tumors are cultured in vitro with a variety of cytokines, including IL-6. Metaphase chromosomes can be obtained from approximately 30% of MM tumors, with this success rate being directly correlated with the extent of karyotypic abnormality and the stage of the tumor. Second, all MM tumors have abnormal karyotypes, and many tumors have numerous and complex chromosome rearrangements, including non-reciprocal rearrangements, that complicate the identi®cation of speci®c chromosomes. Third, the IgH locus (14q32) has a telomeric location, and many of the partner loci have telomeric (4p16; 6p25) or subtelomeric (16q23) locations. Two-or three-color FISH analyses or spectral karyotypic (SKY) analyses of metaphase chromosomes largely solve the second and third problems, with the major exception being that telomeric breakpoints (4p16; 6p25) are not detected by SKY analyses (Sawyer et al., 2000) . Interphase FISH analyses using probes that¯ank an Ig locus to detect split signals or a probe from one end of an Ig locus together with a probe from a speci®c chromosomal region to detect fusion signals permit a comprehensive assessment of Ig translocations in all tumor cells, including MGUS. To minimize the signi®cant background problems with interphase FISH assays, tumor cells have been enriched by pre-selection (e.g., CD-138 magnetic bead selection), or by restricting analysis to cells that express cytoplasmic kappa or lambda IgL (Ahmann et al., 1998; Avet-Loiseau et al., 1999b) .
Sequential hybridization of Southern blots with a comprehensive set of probes that¯ank each kind of switch region (m,g,a,e) eciently identi®es illegitimate switch recombination fragments (ISRF) that hybridize with only one type of either 5' or 3'¯anking switch probe. At least 90% of ISRF detected by this assay in MM cells represent translocation breakpoints into or near IgH switch regions . The t(4;14) translocation generates hybrid transcripts that are eectively detected by an RT ± PCR assay. Since there is no comparable Southern blot assay for translocations into or near JH, D, and V regions, translocations mediated by errors in VDJ recombination or somatic hypermutation can be distinguished only by FISH analysis or cloning. Translocation breakpoints of each kind have been cloned by conventional methods, but also through the use of inverse PCR (Willis et al., 1997) .
Incidence of Ig translocations in MM cell lines, PCL, MM and MGUS
Through a combination of conventional cytogenetics, SKY analyses, metaphase FISH analyses, isolation of molecular clones, and RT ± PCR assays Chesi et al., 1997 Chesi et al., , 1998a Gabrea et al., 1999; Shaughnessy et al., 2001; Shou et al., 2000; Kuehl, 2001, unpublished (Avet-Loiseau et al., 1999b , 1999c Nishida et al., 1997) , it was reported that IgH translocations are present in 36/79 (47%) of MGUS tumors, in approximately 60% of patients with intramedullary MM, and in 70 ± 80% of patients with primary or secondary PCL. Two dierent IgH translocations were identi®ed in 3/40 (8%) PCL tumors, but in less than 1% of intramedullary MM tumors. Using metaphase FISH analyses, we analysed 30 primary MM tumors that had been selected to have an abnormal karyotype and no t(11;14) detected by conventional cytogenetics (Gabrea, 2001, unpublished results) . In this analysis we identi®ed: IgH transloca- (Figure 1 ). These results also suggest that at least 30%, but perhaps as many as 50%, of MM tumors do not have a primary IgH or an IgL translocation.
Anatomy of IgH translocations in MM
Whereas chromosome translocations in myeloid cells typically result in the formation of a fusion protein with a novel or dysregulated function, most Ig translocations in B cell tumors, including MM, result in the dysregulated expression of oncogenes by juxtaposition to Ig regulatory elements (Dalla-Favera and Gaidano, 2001) . There are at least three important enhancer elements that regulate IgH expression in B cells: the intronic enhancer (Em) located in the intron between the JH and switch mu sequences, and two powerful 3' IgH enhancers downstream of the alpha genes (Ea1 and Ea2) (Max, 1999) . In a translocation with a breakpoint in the JH region, all three enhancers remain on the der14 chromosome, so that the dysregulated oncogene is on der14. In contrast, as a result of a reciprocal translocation into a switch region these enhancers become dissociated so that each derivative chromosome has the potential to dysregulate juxtaposed oncogenes (Figure 2) .
Through a combination of strategies, we and others have cloned 40 IgH translocation breakpoints (but no IgL translocation breakpoints) in MM cell lines and tumors Chesi et al., 1996 Chesi et al., , 1997 Chesi et al., , 1998a Gabrea et al., 1999; Hatzivassiliou et al., 2001; Iida et al., 1997; Pratt et al., 2001; Richelda et al., 1997; Ronchetti et al., 1999; Shaughnessy et al., 2001; Bergsagel and Kuehl, 2001, unpublished) . With the exception of a few translocation breakpoints within the JH region, most of these breakpoints were identi®ed using probes designed to detect ISRF, so that the results are signi®cantly biased in identifying translocations that occur within or relatively near an IgH switch region. In any case, a summary of the location of these 40 cloned breakpoints within the IgH locus is provided in Figure 3 . It is clear from analysing this ®gure that the four most frequent recurrent translocations (4p16, 11q13 plus 6p21, and 16q23) have breakpoints that fall within the JH and switch regions, areas that undergo physiologic double-strand DNA breaks induced by somatic mutation and switch recombination, respectively. This is consistent with their mediation by errors in these processes, and is further supported by a more detailed analysis of the breakpoints.
For the t(4; 14) the 5' breakpoints in the IgH locus (on der4, and indicated in Figure 3 as upward vertical line) are mostly located in Sm, with the one exception being located in the Sa1 portion of a hybrid Sm/Sa1. The 3' breakpoints (on der14) are all located signi®cantly downstream, sometimes in Sm but usually in Sg or Sa. This suggests a very speci®c timing for a translocation mediated by the switch recombination machinery. Following the introduction of doublestrand breaks in Sm and a downstream switch region and formation of a covalent circle from the intervening region, there is a failure in the subsequent joining reaction, and the IgH ends are instead joined with other available chromosome ends. There is little if any loss of sequence from chromosome 4 during this process. This diers from the IgH-c-myc translocations reported for murine plasmacytoma tumors, where both breakpoints appear to occur initially within Sm, with subsequent remodeling of the 3' breakpoint to involve a downstream switch region, typically Sa (Kovalchuk et al., 2001 ). In the t(4;14) cases we have analysed there is no evidence that remodeling has occurred.
In contrast to t(4;14) which has all breakpoints into or near switch regions, t(11;14) translocation breakpoints in two of eight cases involved the JH region, consistent with these translocations being mediated by an error in somatic hypermutation (Figure 3) . Nonetheless, translocation breakpoints were near or within IgH switch regions in ®ve of eight cases. We have cloned only one reciprocal pair of breakpoints, but this unique example provides convincing evidence that translocations into IgH switch regions occur at the time of normal IgH switch recombination (Gabrea et al., 1999) . In this case the translocation is actually an insertion of a portion of the IgH locus into 11q13. Approximately 12 kb centromeric to cyclin D1 there is a deletion of 25 bp of 11q13, and an insertion of the IgH segment from Sa1 to Se, that includes the enhancer 3' of alpha-1. By comparison of the insertion breakpoints with the productive m4e switch recombination, it is evident that the inserted region is derived from the productive allele, and represents part of the region that would normally have been excised, converted to a covalent circle, and deleted from the cell following switch recombination. The resultant orientation is 11pter. . .cen. . .myeov. . .//Se..Ea1. . .Sa1// ..cyclinD1. . .11qter. As might be expected, cyclin D1, which is located in the normal physiological position relative to the Ea1 enhancer, is over-expressed. Interestingly, however, myeov, a gene located 300 kb centromeric is not expressed, even though it is dysregulated by the Em enhancer that segregates to der11 in other MM cell lines with reciprocal 11q13 translocations involving an IgH switch region (Janssen et al., 2000) . This result is consistent with the presence of an insulator centromeric to Ea1 that restricts the long distance eects of this enhancer to telomeric genes.
Similar to the t(11;14), the t(14;16) translocation breakpoints occur in the JH region (one case) as well as within or near IgH switch regions (four cases). Unlike 11q13 and 4p16, we have identi®ed two MM cell lines (RPMI-8226; XG-6) in which there is a variant translocation, i.e., t(16;22)(q23;q11). In two (OCI-My5; JJN-3) of three MM cell lines from which we have cloned the breakpoints from both derivatives, we ®nd evidence of large deletions of 16q23 sequences, whereas we found only very small deletions of 4p16 and 11q13 for the three t(4;14) and one t(11;14) translocations in which sequences from both derivatives were obtained. Perhaps the translocation-associated deletions are related to the occurrence of the breakpoints within the fragile site (FRA16D) located in this region (Bednarek et al., 2000; Krummel et al., 2000; Nakazawa et al., 2000; Ried et al., 2000) . The breakpoints on 16q23 also emphasize another feature that is common to the IgH translocations in MM, i.e., they are dispersed over a great distance centromeric to a dysregulated oncogene: 50 ± 100 kb from FGFR3 (4p16), 12 ± 330 kb from cyclin D1 (11q13); and 550 ± 1350 kb from c-maf (16q23).
In striking contrast to the recurrent 4p16, 6p21, 11q13, and 16q23 translocations, the other frequent recurrent translocation partner, 8q24, has IgH breakpoints that often are located outside of the JH and IgH switch regions (Figure 3 ). In fact, most of the t(8;14) translocations in MM are not identi®ed as ISRF by the assay described above. Together with the fact that they are not reported in MGUS, and have been reported in sub-populations of MM cells within a given patient, this supports the hypothesis that these are secondary translocations mediated by non-B cell speci®c mechanisms. Other translocation breakpoints (1q21, 6p25, 20q11, 21q22, 22q12) have been cloned from only a single tumor, are infrequently reported in primary patient samples, and have breakpoints that, like 8q24, fall outside regions of physiologic recombination (Figure 3) . We suspect that most of these may also represent secondary genetic rearrangements associated with tumor progression. 
Translocation partners 11q13 ± cyclin D1
By conventional cytogenetics and interphase FISH analyses the t(11;14)(q13;q32) is present in *15 ± 20% of MM (Avet-Loiseau et al., 1998; Fonseca et al., 1998) . The breakpoints on 14q32 fall within either the JH region, or the switch regions, and are compatible with being mediated by either somatic hypermutation or switch recombination, respectively (Figure 3 ). On 11q13, the breakpoints are dispersed over 330 kb centromeric to cyclin D1, with no evidence of clustering in the Major Translocation Cluster (MTC) described for Mantle Cell Lymphoma (MCL) (Janssen et al., 2000) . This dierence may re¯ect the dierent mechanisms responsible for the translocations, as those in MCL are ascribed to errors in V(D)J recombination, which may more speci®cally target the MTC. Alternatively it may re¯ect dierences in accessibility of the bcl-1 locus at dierent stages of B cell development.
Normally B cells express cyclin D2 and cyclin D3, but not cyclin D1. As a result of the translocation cyclin D1 is juxtaposed to the powerful IgH 3' enhancer(s) on der(14), and its expression is dysregulated. The exact nature of this dysregulation has not been well characterized, and it is not known if it results in an ampli®cation of cyclic levels of cyclin D1 mRNA expression, or in a loss of cell cycle control of mRNA levels and high-level tonic expression of cyclin D1 mRNA. When the translocation breakpoint falls within a switch region, the intronic enhancer (and Ea1 if the breakpoint occurs downstream of this enhancer) end up on der(11) where they may be associated with the ectopic expression of a gene, myeov (myeloma over-expressed gene), located 360 kb centromeric to cyclin D1. This gene, which was identi®ed using DNA from a gastric carcinoma in a transformation assay, has no signi®cant sequence homology to other proteins and was found upregulated in 3/7 MM cell lines with 11q13 translocations (Janssen et al., 2000) .
6p21 ± cyclin D3
Recently we identi®ed a translocation of 6p21 into switch gamma sequence in a MM cell line (Shaughnessy et al., 2001 ). The breakpoint is located no more than 150 kb centromeric to cyclin D3, and is associated with a sixfold increase level of cyclin D3 expression. We identi®ed the t(6;14) in 1/30 MM cell lines, and in 6/150 patients with abnormal metaphase karyotypes. By microarray analysis we found 3/53 patients with 11q13 6p21 high levels of cyclin D3 expression, and determined that these patients had a juxtaposition of the IgH locus and cyclin D3 by interphase FISH analysis. Another MM tumor had a t(6;22) (p21;q11), so that cyclin D3 is bracketed by the centromeric IgH and telomeric IgL breakpoints. The ®nding of dysregulation of cyclin D1 in *15 ± 20% and of cyclin D3 in 5% of patients highlights the importance of the D-type cyclins in MM. There is one report of a t(12;22) (p13;q11) in a lymphoma with a breakpoint in the negative regulatory element of the cyclin D2 promoter (Qian et al., 1999) . Although no expression data was shown it was postulated to dysregulate cyclin D2. There is also a report of a MM tumor and a MM cell line in which there is a t(12;14) translocation that may re¯ect dysregulation of cyclin D2 (Avet-Loiseau et al., 1999a) . Furthermore it emphasizes the importance of carefully studying the entire cyclin D pathway in MM with particular focus on the inhibitors of CDK4 that have been implicated in other tumors.
4p16.3 ± FGFR3 and MMSET
The t(4;14) is identi®ed in approximately 15% of MM tumors (Avet-Loiseau et al., 1998; Chesi et al., 1998b Chesi et al., , 2001 Malgeri et al., 2000) . The breakpoints occur in the telomeric region of chromosome 4 and result in a karyotypically silent translocation: it cannot be identi®ed by either G-banding or spectral karyotype analysis. In the IgH locus the breakpoints all occur in the switch region, and dissociate the intronic enhancer from the 3' enhancer. The 4p16 breakpoints fall 50 ± 100 kb centromeric to FGFR3 that becomes associated with the 3' enhancer(s) on der14. This region includes the 5' non-coding (largely) exons of MMSET/WHSC1 that becomes dysregulated by juxtaposition to the IgH intronic enhancer, resulting in formation of hybrid mRNA transcripts with the JH and I-mu exons. The hybrid transcripts provide a very speci®c and sensitive means of detecting this translocation. We have not identi®ed any variant translocations, nor any translocations into the JH region, suggesting that dysregulation of both MMSET and FGFR3 may be important in the pathogenesis of MM.
MMSET encodes a nuclear protein with two predicted dominant forms. A short form that includes an HMG domain, and a long form that additionally includes 4 PHD-type zinc ®ngers and a SET domain. It thus shares homology to other PHD and SET domain proteins such as ASH1 and trithorax in drosophila. It also shares these features with MLL1/HRX/ALL1, the gene on 11q23 involved in translocations in acute leukemia, suggesting that it may play a role in the oncogenic transformation of MM cells. This gene falls with the minimally deleted region identi®ed for WolfHirschorn Syndrome, a multiple malformation syndrome characterized by mental retardation and developmental defects resulting from partial deletion of the short arm of one chromosome 4 (Stec et al., 1998) . Although it is felt to be a contiguous gene syndrome, it may be predicted that patients with this syndrome have only one copy of MMSET and it is a likely candidate to contribute to this phenotype.
FGFR3 is one of four high-anity tyrosine kinase receptors for the FGF family of ligands. It is not normally expressed in plasma cells, and is ectopically expressed as a result of the translocation. Activating mutations of the t(4;14) translocated FGFR3 allele are present in a third of the MM cell lines and in some patients, substantiating an oncogenic role for FGFR3 in MM. Interestingly, some of the lines with t(4;14) translocation without FGFR3 mutations contained activating mutations of N or K-ras, but no lines contained mutations of both FGFR3 and ras (Chesi et al., 2001) . This suggests that during tumor progression activation of FGFR3 or ras may provide an equivalent stimulus to the cells (Figure 1 ). Activated FGFR3 has been shown to be an oncogene that can induce transformation in ®broblasts that is inhibited by dominant negative inhibitors of the ras/MAPK pathway. Signaling from FGFR3 in MM has been shown to result in phosphorylation of STAT3 and MAPK, and to synergize with IL6 signals in an IL6-dependent plasmacytoma cell line. FGFR3 signaling can substitute for IL6 for the growth and survival of this line, and inhibition of these signals results in apoptosis (Plowright et al., 2000) . These experiments validate FGFR3 as an important target for experimental therapeutics in t(4;14) MM.
16q23 ± c-maf
Translocation t(14;16) (q32;q23) is identi®ed in 5/39 (13%) MM cell lines, and in 5 ± 10% of patients with MM (Chesi et al., 1998a; Sawyer et al., 1998 Sawyer et al., , 2000 . The ®ve cloned breakpoints on 16q23 occur over a region 550 ± 1350 kb centromeric to c-maf, all but one of them within the 800 kb intron of an oxidoreductase gene, WWOX/FOR (Bednarek et al., 2000; . This region is a common fragile site, FRA16D, that has been found to undergo frequent homozygous deletion in adenocarcinomas of stomach, lung, colon and ovary. Allelic deletions of this region have not been associated with inactivation of the remaining allele so that a possible role as a tumor suppressor gene is unclear. The orientation of transcription of WWOX is from centromere to telomere so that the translocations are not predicted to result in hybrid mRNA transcripts with the IgH locus, but instead the translocations appear to inactivate one allele. Mutations of the remaining allele have not been identi®ed to date (Bergsagel, 2001, unpublished results) . Presumably the DNA doublestrand breaks that occur frequently in this fragile site contribute to the pathogenesis of the t(14;16) translocation. Perhaps only in MM cells is the 3' enhancer suciently active to dysregulate c-maf located at such a distance from the breakpoints, providing a possible reason for the apparent lack of 16q23 translocations in other B cell tumors.
The identi®cation of t(16;22) (q23;q11) translocations with breakpoints telomeric to c-maf (not involving WWOX) serves to delineate the targeted region of dysregulation, and indicates that inactivation of one allele of WWOX by translocation is not required for MM cell transformation by 16q23 translocation. C-maf is the cellular homologue of vmaf, the transforming gene in the avian maf retrovirus. It is a basic zipper transcription factor that can heterodimerize with jun and fos and small maf proteins. In lymphoid cells it has been characterized as a T cell transcription factor expressed speci®cally in TH2 lymphocytes that controls the expression of IL-4 (Ho et al., 1996) . It is expressed at a high level in MM cells with a 16q23 translocation, and at a low to undetectable level in the other MM cell lines. How cmaf contributes to the pathogenesis of MM tumors with t(14;16) remains to be determined.
8q24 (c-myc)
Translocations of 8q24 in MM are complex, and appear to be late events involved in the progression of the disease (Shou et al., 2000) . This is in surprising contrast to their role as a primary event in Burkitt's lymphoma and mouse plasmacytoma. It serves to highlight the importance of c-myc in MM, and suggests that in early stages of MM there may be trans factors present only in the bone marrow microenvironment that serve to up-regulate c-myc. With disease progression, c-myc dysregulation by chromosome translocation may abrogate the requirement for these trans factors and allow for increased and/or extra-medullary growth of the MM cells.
6p25 ± MUM1/IRF-4
A t(6;14) (p25;q32) translocation breakpoint was cloned from a MM cell line and found to occur immediately downstream of the IRF-4 gene, a member of the interferon regulatory factor family active in the control of B cell proliferation and dierentiation (Iida et al., 1997) . This translocation was identi®ed by metaphase FISH analyses in three of 17 (18%) MM cell lines that were screened (Yoshida et al., 1999) . Although IRF-4 is normally expressed in most MM cell lines, the three lines with the translocation expressed much higher levels. IRF-4 was shown to be transforming in ®broblasts, suggesting that it may contribute to the oncogenesis of the MM tumors. The incidence of the t(6;14) (p25;q32) translocation in various stages of primary PC tumors, and role in tumor initiation and/or progression are not clearly established at this time.
1q21-24 ± IRTA1 and IRTA2
Unbalanced non-random translocations of 1q and trisomy 1q21 ± 31 were identi®ed in 20 ± 31% of MM (Hatzivassiliou et al., 2001) . A breakpoint from this region was cloned from the FR4 MM cell line, and resulted in the identi®cation of two novel cell surface receptors homologous to the Fc and inhibitory families. IRTA2 is upregulated in most Burkitt lymphoma cell lines with 1q21 abnormalities. It was also up-regulated in one of three MM cell lines with 1q21 translocations. How this contributes to the pathogenesis of MM remains to be determined. The location of the t(1;14) (q21;q32) breakpoint far downstream of the Sa region suggests that this likely represents a secondary translocation, at least in this tumor cell line. From SKY analyses of 150 tumors, the incidence of the t(1;14) (q21;q32) translocation is about 1 ± 2% of advanced intramedullary MM tumors (Sawyer et al., 1998 (Sawyer et al., , 2000 .
Other partner loci
A few other loci have been reported as infrequent recurrent 14q32 translocation partners in MM (AvetLoiseau et al., 1999a (AvetLoiseau et al., , 2001 Bergsagel et al., 1996; Nishida et al., 1997; Rao et al., 1998; Sawyer et al., 1998 Sawyer et al., , 2000 . Mostly these breakpoints have not been cloned, nor the dysregulated genes characterized. These include 1q10 ± 12, 2p23 (?N-myc), 3q21, 4q22 ± 33, 9p13 (?pax-5), 11q23, 20q12, 21q22 and 22q12. Many other partner loci have been identi®ed only once, but breakpoints involving these loci have not been characterized either by FISH mapping or by molecular cloning.
Concluding thoughts and questions

Incidence of Ig translocations in plasma cell tumors
As summarized above, at least one IgH translocation is present in most MM tumors, and the incidence increases with the stage of the tumor. Moreover, the incidence of multiple independent IgH translocations is similarly correlated with the stage of the tumor, consistent with an accumulation of secondary IgH translocations during tumor progression. The precise incidence of IgL translocations at dierent stages of tumorigenesis remains to be determined, although it seems clear that the incidence of Igl translocations is about 20% in karyotypically abnormal tumors, whereas the incidence of Igk translocations is much lower. The lower incidence of Igl compared to IgH translocations might be explained by the fact that only a minority of IgH translocations are mediated by errors in somatic hypermutation, with the rate of somatic hypermutation being several fold lower for IgL compared to IgH (Brezinschek et al., 1998) . It is thought that the IgL variant 8q24 translocations in Burkitt's lymphoma are mediated by errors in somatic hypermutation, but for that tumor the incidence of Igl and Igk translocations are similar (about 10% each) (Mitelman et al., 2001) . This contrasts to the markedly dierent incidence of Igl vs Igk translocations in MM, a result that remains to be explained. As noted above, at least 30%, but possibly as many as 50%, of MM tumors have no primary Ig translocations.
Primary vs secondary translocations
Apart from an involvement of VDJ recombination, IgH switch recombination, and somatic hypermutation in generating breaks in one of the Ig loci, we have virtually no understanding regarding the selection of the partner loci involved in primary Ig translocations. Unlike many kinds of B cell tumors, all three B cell speci®c DNA modi®cation processes that generate double-stranded breaks in DNA are inactive in PC tumors. As a result secondary translocations would not be expected to involve these B cell speci®c mechanisms. The mechanisms that are involved in secondary translocations remain to be determined, but two observations may be relevant. First, MM tumors often show extreme karyotypic abnormalities that generally are associated with solid tumors, perhaps re¯ecting structural or regulatory abnormalities that aect DNA metabolism (Mitelman et al., 2001; Sawyer et al., 1998) . Second, the anatomy of apparent secondary translocations involving c-myc in MM dier from the anatomy of primary translocations, but share some of the features of translocations seen in lymphoma tumors that occur in non-homologous end joining/p53 double knock-out mice (Di®lippantonio et al., 2000; Ferguson et al., 2000) . In addition to understanding mechanisms, the identi®cation of secondary translocations raises interesting questions, including some of the following: Why are the Ig loci targeted so frequently? Are only a limited number of non-Ig loci involved? What is the basis for dysregulation of an oncogene for translocations that do not involve an Ig locus? Are dierent oncogenes dysregulated by primary and secondary translocations, or is there an overlap?
Anatomy of translocations
Characterization of IgH translocation breakpoints in MM underscores our limited understanding of the consequences of these translocations on gene regulation, and prompts a number of obvious questions. First, what is the distance over which an Ig enhancer can act in MM tumors? Most of the IgH breakpoints in MM are 50 ± 300 kb centromeric to a dysregulated oncogene, but for the t(14;16) translocation, the breakpoints are 550 ± 1300 kb centromeric to c-maf. Assuming no associated deletions in this region of 16q23 (our preliminary FISH mapping studies suggest that there are no major deletions), is this extreme distance related to some structural feature at 16q23, or would this be true more generally? In this regard, it is notable that all of these breakpoints are in a fragile site, and also within the extremely large WWOX transcription unit. Second, can the Ig enhancers work over longer distances in highly dierentiated PC tumors compared to less dierentiated B cell tumors? Although this is possible, translocation breakpoints have been mapped about 300 kb from c-myc in some BL (Zeidler et al., 1994) . Third, how many genes are dysregulated by a translocation? The t(4;14) translocation shows that translocations involving an IgH switch region can result in dysregulation of putative oncogenes on both derivative chromosomes, each under control of a dierent enhancer. However, it is also possible that a single Ig enhancer, which may possess at least some of the properties of a locus control region (LCR), can dysregulate two dierent genes, a result that has been well documented for the LCR in the beta globin locus (Bulger and Groudine, 1999; Dillon et al., 1997; Max, 1999) . In addition, we have learned from studies of the globin locus that although the LCR preferentially aects the closest gene, more distal genes can be selectively expressed at certain stages of development. Thus there is no reason that a translocation must dysregulate the gene that is closest to the translocation breakpoint (and therefore closest to the Ig enhancer).
Biological effects of translocations
We understand little about the biological consequences of oncogene dysregulation by the IgH translocations that have been identi®ed. Perhaps, however, we can begin to think more clearly about this issue by posing some questions. First, why is there an apparent promiscuity of translocation partners (oncogenes) involved in primary IgH translocations despite the fact that four partners (4p16, 6p21, 11q13 and 16q23) seem to account for at least half of primary IgH translocations, whereas no other partner seems to be implicated in more than 1 ± 2% of tumors? This promiscuity of oncogene partners stands in marked contrast to BL (8q24, c-myc), MCL (11q13, cyclin D1) or FCL (18q21, bcl-2), but shares some similarity with DLCL. One possibility is that a long-lived PC has a relatively ®xed phenotype that can tolerate many dierent kinds of oncogene dysregulation. Second, do the primary IgH translocations impact the same pathway? In fact, this seems unlikely since there are examples of tumors that have IgH translocations that dysregulate two of the major four recurrent oncogenes, i.e., FGFR3/MM.SET and c-maf; cyclin D3 and c-maf; FGFR3/MM.SET and cyclin D1. Third, do primary Ig translocations directly result in promotion of proliferation, inhibition of apoptosis, or inhibition of dierentiation of long-lived PC? Although we do not have a clear answer at this time, the involvement of the cyclin D genes suggests that promotion of proliferation is important. None of the translocations seem to implicate genes that inhibit apoptosis, which seems consistent with the phenotype of a long-lived, non-proliferative PC. Fourth, is a primary translocation sucient to cause MGUS? Again, we do not have enough information to answer this question but the apparently universal occurrence of aneuploidy in MGUS suggests that other events are also necessary.
In conclusion, studies reported mainly during the past 5 years provide convincing evidence for an important role of Ig translocations in the pathogenesis of MM. Nonetheless, it is clear that we now have more questions than answers about translocations in MM.
